Get the Stockscreener App
6.70
2.60%
0.17
Design Therapeutics Inc stock is traded at $6.70, with a volume of 65,085.
It is up +2.60% in the last 24 hours and down -11.02% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$6.53
Open:
$6.48
24h Volume:
65,085
Relative Volume:
0.36
Market Cap:
$381.55M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-5.5833
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
+16.93%
1M Performance:
-11.02%
6M Performance:
+37.86%
1Y Performance:
+27.86%
1-Day Range:
$6.43
$6.74
1-Week Range:
$5.73
$7.0592
52-Week Range:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.70 | 371.87M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
What indicators show strength in Design Therapeutics Inc.Weekly Profit Summary & Risk Managed Investment Strategies - newser.com
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Regression analysis insights on Design Therapeutics Inc. performanceJobs Report & High Win Rate Trade Alerts - newser.com
How to recover losses in Design Therapeutics Inc. stockWeekly Trade Report & Weekly Sector Rotation Insights - newser.com
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Update - MarketBeat
What recovery options are there for Design Therapeutics Inc.July 2025 Review & Free Technical Pattern Based Buy Signals - newser.com
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Should you wait for a breakout in Design Therapeutics Inc.Market Risk Summary & Safe Capital Growth Trade Ideas - newser.com
Published on: 2025-10-31 05:37:27 - newser.com
How to integrate Design Therapeutics Inc. into portfolio analysis toolsAnalyst Downgrade & Long-Term Safe Investment Plans - newser.com
Developing predictive dashboards with Design Therapeutics Inc. dataJuly 2025 Action & AI Enhanced Trading Signals - newser.com
Is Design Therapeutics Inc. stock poised for growthJuly 2025 Summary & Real-Time Stock Price Movement Reports - newser.com
Published on: 2025-10-31 00:22:12 - newser.com
Published on: 2025-10-31 00:00:29 - newser.com
Published on: 2025-10-29 02:11:27 - newser.com
Forecasting Design Therapeutics Inc. price range with options data2025 Top Gainers & Daily Chart Pattern Signal Reports - newser.com
How buybacks impact Design Therapeutics Inc. stock valueJuly 2025 Highlights & Entry and Exit Point Strategies - fcp.pa.gov.br
Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy - TipRanks
Design Therapeutics Advances DT-216P2 Study for Friedreich’s Ataxia - TipRanks
Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia - TipRanks
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):